Molecular structure of Fludarabine, CAS Number: 21679-14-1
Fludarabine (CAS 21679-14-1)
See product citations (15)
Alternate Names:
2-Fluoroadenine-9-β-D-arabinofuranoside
Application:
Fludarabine is a cell permeable agent that interferes with DNA synthesis and repair; also inhibits RNA transcription
CAS Number:
21679-14-1
Purity:
≥99%
Molecular Weight:
285.2
Molecular Formula:
C10H12FN5O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Fludarabine, a purine analog, plays a pivotal role in the study of cellular mechanisms and cancer research due to its ability to interfere with DNA synthesis. This nucleotide analog integrates into DNA strands, leading to chain termination during DNA replication. By mimicking adenosine, fludarabine is phosphorylated within cells to its active triphosphate form, fludarabine triphosphate, which competes with natural nucleotides for incorporation into DNA. This incorporation results in the inhibition of DNA polymerase, an enzyme critical for DNA replication and repair, thereby causing cell cycle arrest and apoptosis in rapidly dividing cells. Its mechanism elucidates the cellular pathways involved in DNA synthesis and repair, providing valuable insights for the development of novel strategies in cancer research. The study of fludarabine′s effects on DNA synthesis and cellular metabolism enhances our understanding of the molecular dynamics of cell proliferation and death, serving as a cornerstone for exploring therapeutic targets in oncology and beyond.
Fludarabine (CAS 21679-14-1) References
- Fludarabine in Waldenstrom's macroglobulinemia. | Leblond, V. and Choquet, S. 2003. Semin Oncol. 30: 239-42. PMID: 12720144
- Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia. | Leporrier, M. 2004. Hematol J. 5 Suppl 1: S10-9. PMID: 15079149
- Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. | Hallek, M. and Eichhorst, BF. 2004. Hematol J. 5 Suppl 1: S20-30. PMID: 15079150
- Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies. | Johnson, SA. 2004. Hematol J. 5 Suppl 1: S50-61. PMID: 15079153
- Fludarabine: a review of its use in non-Hodgkin's lymphoma. | Anderson, VR. and Perry, CM. 2007. Drugs. 67: 1633-55. PMID: 17661532
- Fludarabine: a review of the clear benefits and potential harms. | Lukenbill, J. and Kalaycio, M. 2013. Leuk Res. 37: 986-94. PMID: 23787174
- Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia. | Pandzic, T., et al. 2016. Clin Cancer Res. 22: 6217-6227. PMID: 26957556
- Fludarabine resistance mediated by aminoglycoside-3'-phosphotransferase-IIa and the structurally related eukaryotic cAMP-dependent protein kinase. | Sánchez-Carrera, D., et al. 2017. FASEB J. 31: 3007-3017. PMID: 28373209
- Fludarabine and neurotoxicity in engineered T-cell therapy. | Lowe, KL., et al. 2018. Gene Ther. 25: 176-191. PMID: 29789639
- Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. | Langenhorst, JB., et al. 2019. Blood Adv. 3: 2179-2187. PMID: 31324638
- Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71. | Gao, C., et al. 2021. Viruses. 13: PMID: 33925713
- Prophylactic strategies to meet infectious complications in fludarabine-treated CLL. | Südhoff, T., et al. 1997. Leukemia. 11 Suppl 2: S38-41. PMID: 9178837
- Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. | Adkins, JC., et al. 1997. Drugs. 53: 1005-37. PMID: 9179529
Inhibitor of:
2010002M12Rik, 6030422M02Rik, Adad2, ADK, AL, AMDHD2, AMPD1, APRT, Asparagine synthetase, Atase, BUP-1, C15orf42, C6orf167, CD1C, CD22, CD79B, CEACAM18, Clb5, CNTF, CRLF3, CTPS1, dCK, DERA, DGUOK, DNA pol α, DNA pol β, DNA pol δ cat, DNA pol ν, dNT-1, DTYMK, E430018J23Rik, EG240038, EG240327, EG245263, EG382639, EG384244, EG434179, EG628359, GHS-R1, Gight chain, GM-CSFRα, GMPPB, GMPR1, GPSN2, GUCD1, GUK1, Hairy, Hairy Cell Leukemia Marker, Hfm1, HISPPD2A, HS6ST1, HSV-1 VP22, IFIT1, IFN-α1, IFN-α14, IFN-α21, IFN-γ, IFN-τ, Ig κ, Ig λ, Ig λ chain V4A, Ig λ light chain, IgG Fab fragment, IgG light chain, IgG2c, IgH-VJ558, IgHg, Igk-C, IgM, IL-12Rβ1, IL-15, IL-27Rα, IL-3R, Interferon inducible (IFI, IFIT), IRF-6, ISYNA1, ITI-H3, KIAA1958, LOC345643, LOC644196, Might chain, MYADML2, NASP, Nucleoside Monophosphate Kinase, OAS (2′-5′-oligoadenylate synthetase), Ob, Olr532, Olr694, OTTMUSG00000011268, OTTMUSG00000011270, OTTMUSG00000011272, OTTMUSG00000011273, OTTMUSG00000011282, OTTMUSG00000011285, OTTMUSG00000011289, OTTMUSG00000011291, OTTMUSG00000011339, OTTMUSG00000011350, OTTMUSG00000016644, PAPD5, PIG-YL, Placental RNase inhibitor, PNP2, Pol III RPC32, Pol2, Ppat, PPC Synthetase, PRIM1, PRPS1L1, PRPS2, PRPS3, PRPSAP2, PRTFDC1, PUSL1, R2, REPIN1, REXO1, REXO2, RFC, RFC3, RFPL3, RNGTT, Rnr1, Rpp21, SAMHD1, SLC29 (solute carrier family 29), SLC35F1, SNM1A, SP140L, Stat, Stat1, T Cell Marker, T-cell receptor Vδ 2, Trav12-1, Trav12n-1, TSARG2, TSLP, UPase 2, UPRT, and XTP3TPA.Activator of:
ADK, ADO, BCMP1, Bu-1a, CD38, CDD, CMPK, CNT3, CXCR-3, GBP1, HVEM, I830012O16Rik, IFIT1L, IFN-α8, IL-31R, ITPase, JAK1, Lnk, NT5C2, NUDT15, OASL1, PD-ECGF, Pdcd-1L2, PIAS 3, RFC2, RNase HII-C, SH2D1A, TECK, Tyk 2, UCK1, and ZNF425.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Fludarabine, 5 mg | sc-204755 | 5 mg | $58.00 | |||
Fludarabine, 25 mg | sc-204755A | 25 mg | $204.00 |